Afficher la notice abrégée
dc.creator | Loukides, S. | en |
dc.creator | Kostikas, K. | en |
dc.creator | Bakakos, P. | en |
dc.date.accessioned | 2015-11-23T10:38:11Z | |
dc.date.available | 2015-11-23T10:38:11Z | |
dc.date.issued | 2009 | |
dc.identifier.issn | 1105848X | |
dc.identifier.uri | http://hdl.handle.net/11615/30420 | |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-77953471171&partnerID=40&md5=785febbc8758612990254c8f2b98e2a1 | |
dc.subject | beta 2 adrenergic receptor stimulating agent | en |
dc.subject | budesonide | en |
dc.subject | corticosteroid | en |
dc.subject | formoterol | en |
dc.subject | leukotriene receptor blocking agent | en |
dc.subject | long acting drug | en |
dc.subject | montelukast | en |
dc.subject | placebo | en |
dc.subject | salbutamol | en |
dc.subject | asthma | en |
dc.subject | clinical trial | en |
dc.subject | combination chemotherapy | en |
dc.subject | disease exacerbation | en |
dc.subject | disease severity | en |
dc.subject | dosage schedule comparison | en |
dc.subject | dose response | en |
dc.subject | drug efficacy | en |
dc.subject | drug intermittent therapy | en |
dc.subject | drug treatment failure | en |
dc.subject | editorial | en |
dc.subject | forced expiratory volume | en |
dc.subject | human | en |
dc.subject | low drug dose | en |
dc.subject | lung function | en |
dc.subject | monotherapy | en |
dc.subject | morbidity | en |
dc.subject | peak expiratory flow | en |
dc.subject | recommended drug dose | en |
dc.subject | treatment outcome | en |
dc.title | Do we overtreat mild persistent asthma? | en |
dc.type | journalArticle | en |
Fichier(s) constituant ce document
Il n'y a pas de fichiers associés à ce document.
|
Ce document figure dans la(les) collection(s) suivante(s)
Afficher la notice abrégée